vs
Side-by-side financial comparison of Crexendo, Inc. (CXDO) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
Crexendo, Inc. is the larger business by last-quarter revenue ($18.1M vs $16.1M, roughly 1.1× Journey Medical Corp). Crexendo, Inc. runs the higher net margin — 6.7% vs -7.8%, a 14.5% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 11.2%). Over the past eight quarters, Crexendo, Inc.'s revenue compounded faster (12.4% CAGR vs 11.0%).
Crexendo, Inc. is a U.S.-headquartered cloud communications technology provider. It delivers unified communications as a service (UCaaS), contact center solutions, business VoIP services, and collaborative work tools, primarily catering to small and medium-sized enterprises operating in the North American market.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
CXDO vs DERM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.1M | $16.1M |
| Net Profit | $1.2M | $-1.2M |
| Gross Margin | — | — |
| Operating Margin | 6.3% | -2.8% |
| Net Margin | 6.7% | -7.8% |
| Revenue YoY | 11.2% | 27.3% |
| Net Profit YoY | 140.2% | -182.0% |
| EPS (diluted) | $0.03 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.1M | $16.1M | ||
| Q3 25 | $17.5M | $17.0M | ||
| Q2 25 | $16.6M | $15.0M | ||
| Q1 25 | $16.1M | $13.1M | ||
| Q4 24 | $16.2M | $12.6M | ||
| Q3 24 | $15.6M | $14.6M | ||
| Q2 24 | $14.7M | $14.9M | ||
| Q1 24 | $14.3M | $13.0M |
| Q4 25 | $1.2M | $-1.2M | ||
| Q3 25 | $1.4M | $-2.3M | ||
| Q2 25 | $1.2M | $-3.8M | ||
| Q1 25 | $1.2M | $-4.1M | ||
| Q4 24 | $507.0K | $1.5M | ||
| Q3 24 | $148.0K | $-2.4M | ||
| Q2 24 | $588.0K | $-3.4M | ||
| Q1 24 | $434.0K | $-10.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 82.3% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 56.0% | ||
| Q1 24 | — | 47.7% |
| Q4 25 | 6.3% | -2.8% | ||
| Q3 25 | 7.5% | -9.0% | ||
| Q2 25 | 6.7% | -19.2% | ||
| Q1 25 | 7.2% | -25.3% | ||
| Q4 24 | 3.9% | 17.7% | ||
| Q3 24 | 0.9% | -19.8% | ||
| Q2 24 | 3.9% | -19.7% | ||
| Q1 24 | 3.4% | -77.4% |
| Q4 25 | 6.7% | -7.8% | ||
| Q3 25 | 8.3% | -13.6% | ||
| Q2 25 | 7.4% | -25.3% | ||
| Q1 25 | 7.3% | -31.0% | ||
| Q4 24 | 3.1% | 12.1% | ||
| Q3 24 | 0.9% | -16.3% | ||
| Q2 24 | 4.0% | -22.6% | ||
| Q1 24 | 3.0% | -80.1% |
| Q4 25 | $0.03 | $-0.04 | ||
| Q3 25 | $0.05 | $-0.09 | ||
| Q2 25 | $0.04 | $-0.16 | ||
| Q1 25 | $0.04 | $-0.18 | ||
| Q4 24 | $0.03 | $0.10 | ||
| Q3 24 | $0.00 | $-0.12 | ||
| Q2 24 | $0.02 | $-0.17 | ||
| Q1 24 | $0.01 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $24.1M |
| Total DebtLower is stronger | $114.0K | $25.3M |
| Stockholders' EquityBook value | $63.8M | $31.9M |
| Total Assets | $77.7M | $94.6M |
| Debt / EquityLower = less leverage | 0.00× | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $24.1M | ||
| Q3 25 | — | $24.9M | ||
| Q2 25 | — | $20.3M | ||
| Q1 25 | — | $21.1M | ||
| Q4 24 | — | $20.3M | ||
| Q3 24 | — | $22.5M | ||
| Q2 24 | — | $23.9M | ||
| Q1 24 | — | $24.1M |
| Q4 25 | $114.0K | $25.3M | ||
| Q3 25 | $236.0K | $25.2M | ||
| Q2 25 | $356.0K | $25.1M | ||
| Q1 25 | $475.0K | $25.0M | ||
| Q4 24 | $592.0K | $24.9M | ||
| Q3 24 | $709.0K | $19.8M | ||
| Q2 24 | $823.0K | $19.7M | ||
| Q1 24 | $937.0K | $14.7M |
| Q4 25 | $63.8M | $31.9M | ||
| Q3 25 | $61.3M | $25.9M | ||
| Q2 25 | $58.3M | $19.2M | ||
| Q1 25 | $55.2M | $21.5M | ||
| Q4 24 | $51.4M | $20.1M | ||
| Q3 24 | $49.5M | $10.9M | ||
| Q2 24 | $48.2M | $11.3M | ||
| Q1 24 | $46.8M | $13.0M |
| Q4 25 | $77.7M | $94.6M | ||
| Q3 25 | $76.0M | $85.2M | ||
| Q2 25 | $71.4M | $81.2M | ||
| Q1 25 | $67.4M | $85.0M | ||
| Q4 24 | $64.9M | $80.2M | ||
| Q3 24 | $62.3M | $64.0M | ||
| Q2 24 | $59.6M | $65.2M | ||
| Q1 24 | $57.5M | $66.6M |
| Q4 25 | 0.00× | 0.79× | ||
| Q3 25 | 0.00× | 0.97× | ||
| Q2 25 | 0.01× | 1.30× | ||
| Q1 25 | 0.01× | 1.16× | ||
| Q4 24 | 0.01× | 1.24× | ||
| Q3 24 | 0.01× | 1.81× | ||
| Q2 24 | 0.02× | 1.75× | ||
| Q1 24 | 0.02× | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.3M | $-6.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 1.93× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.3M | $-6.3M | ||
| Q3 25 | $4.4M | $-2.4M | ||
| Q2 25 | $1.3M | $-942.0K | ||
| Q1 25 | $1.2M | $-2.8M | ||
| Q4 24 | $2.2M | $2.2M | ||
| Q3 24 | $1.6M | $-1.2M | ||
| Q2 24 | $2.7M | $-5.2M | ||
| Q1 24 | $-166.0K | $-5.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $1.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | 1.93× | — | ||
| Q3 25 | 3.05× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 4.29× | 1.46× | ||
| Q3 24 | 10.95× | — | ||
| Q2 24 | 4.51× | — | ||
| Q1 24 | -0.38× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CXDO
| Services | $8.6M | 48% |
| Software Solution Segment | $8.3M | 46% |
| Products | $1.1M | 6% |
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
